Transpek Inds.

how big is Transpek Inds.?

As of Jun 06, Transpek Industry Ltd has a market capitalization of 907.10 Cr, classifying it as a Micro Cap company, with recent net sales of 649.86 Cr and net profit of 48.74 Cr.

Market Cap: As of Jun 06, Transpek Industry Ltd has a market capitalization of 907.10 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported a sum of Net Sales of 649.86 Cr and a sum of Net Profit of 48.74 Cr. This data is on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: The balance sheet data is also on a Consolidated basis for the latest annual period ending in Mar'24. Shareholder's Funds are reported at 673.39 Cr, while Total Assets amount to 965.67 Cr.

Who are the top shareholders of the Transpek Inds.?

The top shareholders of Transpek Industries include Anshul Specialty Molecules Private Limited with 24.64%, individual investors holding 31.39%, and Mukul Mahavir Agrawal as the largest public shareholder at 2.12%. There are no pledged promoter holdings or mutual funds invested in the company.

The top shareholders of Transpek Industries include the promoters, who hold the majority of the shares. The promoter with the highest holding is Anshul Specialty Molecules Private Limited, which owns 24.64% of the company. Additionally, individual investors collectively hold 31.39% of the shares. In terms of public shareholders, Mukul Mahavir Agrawal is the highest with a holding of 2.12%. There are also three foreign institutional investors (FIIs) that hold a small percentage of 0.03%. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

When is the next results date for Transpek Inds.?

No Upcoming Board Meetings

What does Transpek Inds. do?

Transpek Industry Limited is a global supplier of chlorinated products for sectors like pharmaceuticals and agrochemicals, with a market cap of Rs 905 Cr and reported net sales of 165 Cr and net profit of 19 Cr for the quarter ending March 2025. Key metrics include a P/E of 19.00 and a dividend yield of 0.87%.

Overview:<BR>Transpek Industry Limited is a leading global supplier of chlorinated products in the commodity chemicals industry, catering to sectors such as pharmaceuticals, agrochemicals, dyes, and pigments.<BR><BR>History:<BR>Transpek Industry Limited was incorporated in an unspecified year and has maintained its status as a micro-cap company. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 165 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 19 Cr (Quarterly Results - Mar 2025)<BR>- Market-cap: Rs 905 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 19.00<BR>- Industry P/E: 47<BR>- Dividend Yield: 0.87%<BR>- Debt Equity: -0.05<BR>- Return on Equity: 6.54%<BR>- Price to Book: 1.21<BR><BR>Contact Details:<BR>Address: 4th Floor, Gotri Sevasi Road Vadodara Gujarat : 390021<BR>Tel: 91-265-2335444/2335446/2335447/141<BR>Email: secretarial@transpek.com<BR>Website: http://www.transpek.com

Who are in the management team of Transpek Inds.?

As of March 2023, the management team of Transpek Inds. includes A C Shroff (Chairman), Bimal V Mehta (Managing Director), Avtar Singh (Joint Managing Director), and several independent and non-executive directors. This diverse team oversees the company's governance and management.

As of March 2023, the management team of Transpek Inds. includes the following individuals:<BR><BR>1. A C Shroff - Chairman & Non Executive Director<BR>2. A G Shroff - Non Executive Director<BR>3. Bimal V Mehta - Executive Director / Managing Director / Non Promoter<BR>4. D K Shroff - Non Executive Director<BR>5. Ravi A Shroff - Non Executive Director<BR>6. Bernd Dill - Independent Non Executive Director<BR>7. Ninad D Gupte - Independent Non Executive Director<BR>8. Nimishbhai U Patel - Independent Non Executive Director<BR>9. Geeta Goradia - Independent Non Executive Director<BR>10. Hemantkumar J Bhatt - Independent Non Executive Director<BR>11. A M Tiwari - Independent Non Executive Director<BR>12. Avtar Singh - Joint Managing Director<BR><BR>This team comprises a mix of executive and non-executive directors, contributing to the governance and management of the company.

Has Transpek Inds. declared dividend?

Transpek Industry Ltd has declared a 140% dividend, amounting to ₹14 per share, with an ex-date of September 13, 2024. While the company shows mixed total returns over various periods, it has experienced negative returns in the short term and positive trends in the longer term.

Transpek Industry Ltd has declared a 140% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 140%<BR>- Amount per share: 14<BR>- Ex-date: 13 Sep 24<BR><BR>Dividend Yield: 0.87%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -1.75%, the dividend return was 0%, resulting in a total return of -1.75%.<BR><BR>Over the past year, the price return was -5.14%, the dividend return was 0.78%, leading to a total return of -4.36%.<BR><BR>In the last 2 years, the price return was -18.2%, the dividend return was 1.94%, which resulted in a total return of -16.26%.<BR><BR>For the 3-year period, the price return was 0.89%, the dividend return was 4.46%, culminating in a total return of 5.35%.<BR><BR>In the 4-year span, the price return was 8.12%, the dividend return was 4.36%, producing a total return of 12.48%.<BR><BR>Over the last 5 years, the price return was -7.51%, the dividend return was 4.76%, resulting in a total return of -2.75%.<BR><BR>Overall, Transpek Industry Ltd has declared a substantial dividend, but the total returns over various periods show a mixed performance, with negative returns in the shorter terms and a positive trend in the longer terms.

Who are the peers of the Transpek Inds.?

Transpek Inds. peers include Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Sadhana Nitro, POCL Enterprises, Indo Borax & Ch., and Primo Chemicals. Transpek Inds. has below-average management risk and a 1-year return of -2.29%, higher than Sadhana Nitro but lower than POCL Enterprises, which leads with a 236.24% return.

Peers: The peers of Transpek Inds. are Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Sadhana Nitro, POCL Enterprises, Indo Borax & Ch., and Primo Chemicals.<BR><BR>Quality Snapshot: Excellent management risk is observed at GHCL, while Good management risk is found at Chemplast Sanmar and the rest. Average management risk is present at Tata Chemicals, India Glycols, Sadhana Nitro, POCL Enterprises, Indo Borax & Ch., and Primo Chemicals. Below Average management risk is noted at Fischer Medical and Transpek Inds. Growth is Excellent at POCL Enterprises, while Below Average growth is seen at Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Sadhana Nitro, Indo Borax & Ch., Primo Chemicals, and Transpek Inds. Average growth is noted at Fischer Medical. Capital Structure is Excellent at GHCL and Indo Borax & Ch., Good at Fischer Medical and Transpek Inds., and Below Average at Chemplast Sanmar, India Glycols, Sadhana Nitro, POCL Enterprises, and Primo Chemicals.<BR><BR>Return Snapshot: The peer with the highest 1-year return is POCL Enterprises at 236.24%, while the lowest is Sadhana Nitro at -53.28%. Transpek Inds. has a 1-year return of -2.29%, which is higher than Sadhana Nitro but lower than POCL Enterprises. Additionally, Sadhana Nitro and Primo Chemicals have negative six-month returns.

How has been the historical performance of Transpek Inds.?

Transpek Inds. experienced fluctuating financial performance, with net sales increasing to 649.85 Cr in March 2025 but declining from 826.90 Cr in March 2023. Despite revenue challenges, the company showed resilience with improved operating profit, profit before tax, and cash flow from operating activities.

Answer:<BR>The historical performance of Transpek Inds. shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Transpek Inds. reported net sales of 649.85 Cr in March 2025, an increase from 579.63 Cr in March 2024, but a decline from 826.90 Cr in March 2023. The total operating income followed a similar pattern, reaching 649.85 Cr in March 2025 compared to 579.63 Cr in the previous year. The raw material cost rose to 330.33 Cr in March 2025 from 293.86 Cr in March 2024, contributing to a total expenditure of 555.17 Cr, up from 497.32 Cr in March 2024. Operating profit (PBDIT) increased to 123.39 Cr in March 2025 from 107.47 Cr in March 2024, while profit before tax also rose to 61.66 Cr from 55.51 Cr. However, profit after tax saw a more modest increase to 48.74 Cr from 38.56 Cr. The earnings per share (EPS) improved to 87.19 in March 2025 from 68.98 in March 2024. On the balance sheet, total assets grew to 1,000.54 Cr in March 2025 from 965.67 Cr in March 2024, and total liabilities also increased to 1,000.54 Cr from 965.67 Cr. Cash flow from operating activities rose to 135.00 Cr in March 2025 from 97.00 Cr in March 2024, indicating improved cash generation capabilities. Overall, while Transpek Inds. faced some challenges in revenue, it demonstrated resilience in profitability and asset growth.

Is Transpek Inds. overvalued or undervalued?

As of November 17, 2025, Transpek Industries is fairly valued with a PE ratio of 13.02, making it an attractive investment compared to its peers, despite a year-to-date return of -13.69%.

As of 17 November 2025, the valuation grade for Transpek Industries has moved from expensive to fair. The company is currently fairly valued, with a PE ratio of 13.02, a Price to Book Value of 0.99, and an EV to EBITDA of 6.53. These ratios indicate a reasonable valuation compared to its peers in the commodity chemicals sector.<BR><BR>In comparison to its peers, Transpek's valuation appears attractive, especially when contrasted with Solar Industries, which has a PE ratio of 95.31, and Gujarat Fluoroch, with a PE of 57.85, both classified as very expensive. Additionally, Aarti Industries, another peer, has a fair valuation with a PE of 53.15. Despite recent stock performance lagging behind the Sensex, with a year-to-date return of -13.69% compared to the Sensex's 8.72%, the current valuation metrics suggest that Transpek Industries offers a compelling investment opportunity within its sector.

Is Transpek Inds. technically bullish or bearish?

As of November 19, 2025, Transpek Inds. has a bearish technical trend with moderate strength, indicated by bearish daily moving averages and Bollinger Bands, while the MACD and KST show mixed signals, contributing to its underperformance compared to the Sensex.

As of 19 November 2025, the technical trend for Transpek Inds. has changed from mildly bearish to bearish. The current technical stance is bearish with moderate strength. Key indicators driving this stance include the bearish signals from the daily moving averages and the Bollinger Bands on both weekly and monthly time frames. The MACD shows a mildly bullish signal on the weekly but is bearish on the monthly, indicating a lack of consistent momentum. Additionally, the KST is mildly bullish on the weekly but bearish on the monthly, further supporting the bearish outlook. Overall, the stock has underperformed significantly compared to the Sensex across multiple time frames, reinforcing the bearish sentiment.

Are Transpek Industry Ltd latest results good or bad?

Transpek Industry Ltd's latest results show a year-on-year profit increase of 32.49%, but Q3 FY26 reveals a decline in net sales and a 14.16% drop in quarterly net profit, indicating operational challenges that could affect future performance. Investors should consider these mixed results when evaluating the company's outlook.

Transpek Industry Ltd's latest results present a mixed picture. On one hand, the company has reported a year-on-year profit increase of 32.49% for the nine-month period, which is a positive sign. However, the quarterly performance for Q3 FY26 shows concerning trends. <BR><BR>Net sales have declined by 1.12% sequentially and 6.80% year-on-year, indicating ongoing top-line challenges. The net profit for the quarter is ₹10.85 crores, which reflects a significant drop of 14.16% compared to the previous quarter, although it is up 1.88% year-on-year. <BR><BR>Additionally, the operating margins have contracted to 15.73% from 16.65% in the previous quarter, highlighting pressure on profitability. The PAT margin also decreased, which raises concerns about the company's ability to maintain its profitability amidst declining revenues.<BR><BR>Overall, while the long-term profit growth is encouraging, the recent quarterly results suggest that Transpek is facing operational headwinds that could impact its future performance. Investors may need to weigh these mixed results carefully when considering the company's outlook.

Should I buy, sell or hold Transpek Industry Ltd?

Which are the latest news on Transpek Inds.?

Why is Transpek Industry Ltd falling/rising?

As of 08-Feb, Transpek Industry Ltd's stock price is currently 1,169.95, showing a slight daily increase but a year-to-date decline of 7.73%. While there is short-term positive momentum and increased investor participation, the stock remains below its moving averages, indicating a longer-term downward trend.

As of 08-Feb, Transpek Industry Ltd's stock price is rising slightly, with a current price of 1,169.95, reflecting a change of 3.35 (0.29%) upward. Despite this daily increase, the stock has shown a negative performance over longer periods, with a year-to-date decline of 7.73% and a one-year drop of 26.99%. <BR><BR>Today, the stock outperformed its sector by 1.09%, indicating some positive momentum in the short term. However, it touched an intraday low of Rs 1135, which represents a decrease of 2.71%. Additionally, the stock is trading lower than its moving averages across various time frames (5-day, 20-day, 50-day, 100-day, and 200-day), suggesting a longer-term downward trend. <BR><BR>On a positive note, there has been a significant increase in investor participation, with delivery volume rising by 150.95% against the 5-day average, indicating growing interest among investors. Despite the current rise in price, the overall performance metrics suggest that the stock has been struggling in the longer term.